Reinforcement of the intestinal mucus layer protects against clostridium difficile intestinal injury in vitro

Journal of the American College of Surgeons

Volumn 219, Issue 3, 2014, Pages 460-468

  Diebel, Lawrence N ^a   Liberati, David M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Abbreviations and Acronyms; CDI; Clostridium difficile infection; FITC; fluorescein isothiocyanate; IEC; IL; interleukin; intestinal epithelial cell; PC; phosphatidylcholine; secretory immunoglobulin A; SIgA; TNF; tumor necrosis factor

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; INTERLEUKIN 6; SECRETORY IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA; CLOSTRIDIUM DIFFICILE TOXIN B; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; METHOTREXATE; PHOSPHATIDYLCHOLINE; PROTECTIVE AGENT;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COCULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCUS; INTESTINE NECROSIS; MUCUS; PRIORITY JOURNAL; TRANSCYTOSIS; ANIMAL CELL; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST RESISTANCE; HT 29 CELL LINE; INTESTINE FUNCTION; INTESTINE INJURY; INTESTINE MUCOSA; MOUSE; NONHUMAN; PROTEIN ANALYSIS; CELL CULTURE; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; ENTEROPATHY; INTESTINE; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

CELLS, CULTURED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; INTESTINAL DISEASES; INTESTINES; MUCUS; PHOSPHATIDYLCHOLINES; PROTECTIVE AGENTS;

EID: 84906794487     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2014.05.005     Document Type: Article

References (41)

1. S. Aslam, R.J. Hamill, and D.M. Musher Treatment of Clostridium difficile-associated disease: old therapies and new strategies Lancet Infect Dis 5 2005 549 557
2. M. Wilcox, and J. Minton Role of antibody response in outcome of antibiotic-associated diarrhoea Lancet 357 2001 158 159
3. V.G. Loo, A.M. Bourgault, and L. Poirier et al. Host and pathogen factors for Clostridium difficile infection and colonization N Engl J Med 365 2011 1693 1703
4. R. Madan, and W.A. Petri Jr. Immune responses to Clostridium difficile infection Trends Mol Med 18 2012 658 666
5. R.E. El Feghaly, J.L. Stauber, and E. Deych et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection Clin Inf Dis 56 2013 1713 1721
6. G. Vedantam, A. Clark, and M. Chu et al. Clostridium difficile infection - toxins and non-toxin virulence factors, and their contributions to disease establishment and host response Gut Microbes 3 2012 121 134
7. G.P. Carter, J.I. Rood, and D. Lyras The role toxin A and toxin B in the virulence of Clostridium difficile Trends Microbiol 20 2012 21 29
8. S.A. Kuehne, S.T. Cartman, and N.P. Minton Both, toxin A and toxin B, are important in Clostridium difficile infection Gut Microbes 2 2011 252 255
9. S. Sirard, L. Valiquette, and L.C. Fortier Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes J Clin Microbiol 49 2011 4040 4046
10. C.A. Müller, I.B. Autenrieth, and A. Peschel Innate defenses of the intestinal epithelial barrier Cell Mol Life Sci 62 2005 1297 1307
11. T. Giesemann, G. Guttenberg, and K. Aktories Human alpha-defensins inhibit Clostridium difficile toxin B Gastroenterology 134 2008 2049 2058
12. V. Liévin-Le Moal, and A.L. Servin The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota Clin Microbiol Rev 19 2006 315 337
13. P. Dharmani, V. Srivastava, V. Kissoon-Singh, and K. Chadee Role of intestinal mucins in innate host defense mechanisms against pathogens J Innate Immun 1 2009 123 135
14. B. Deplancke, and H.R. Gaskins Microbial modulation of innate defense: goblet cells and the intestinal mucus layer Am J Clin Nutr 73 2001 1131S 1141S
15. R. Ehehalt, A. Braun, and M. Karner et al. Phosphatidylcholine as a constituent in the colonic mucosal barrier - physiological and clinical relevance Biochim Biophys Acta 1801 2010 983 993
16. W. Stremmel, R. Ehehalt, and S. Staffer et al. Mucosal protection by phosphatidylcholine Dig Dis 30 2012 85 91
17. P. Brandtzaeg Update on mucosal immunoglobulin A in gastrointestinal disease Curr Opin Gastroenterol 26 2010 554 563
18. P. Brandtzaeg Secretory IgA: designed for anti-microbial defense Front Immunol 4 2013 222 238
19. B. Corthésy Multi-faceted functions of secretory IgA at mucosal surfaces Front Immunol 4 2013 185 195
20. J.E. Branka, G. Vallette, and A. Jarry et al. Early functional effects of Clostridium difficile toxin A on human colonocytes Gastroenterology 112 1997 1887 1894
21. A. Olson, L.N. Diebel, and D.M. Liberati Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury J Trauma Acute Care Surg 74 2013 983 990
22. I. Treede, A. Braun, and R. Sparla et al. Anti-inflammatory effects of phosphatidylcholine J Biol Chem 282 2007 27155 27164
23. I. Treede, A. Braun, and P. Jeliaskova et al. TNF-α-induced up-regulation of proinflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells BMC Gastroenterol 9 2009 53 63
24. W. Stremmel, A. Hanemann, and A. Braun et al. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis - a review of three clinical trials Expert Opin Investig Drugs 19 2010 1623 1630
25. D.N. Gerding, and S. Johnson Management of Clostridium difficile infection: thinking inside and outside the box Clin Inf Dis 51 2010 1306 1313
26. K. Solomon, A.J. Martin, and C. O'Donoghue et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses J Med Microbiol 62 2013 1453 1460
27. C.P. Kelly, and L. Kyne The host immune response to Clostridium difficile J Med Microbiol 60 2011 1070 1079
28. S. Fujitani, W.L. George, and A.R. Murthy Comparison of clinical severity score indices for Clostridium difficile infection Infect Control Hosp Epidemiol 32 2011 220 228
29. R.H. Morrison, N.S. Hall, and M. Said et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection Clin Inf Dis 53 2011 1173 1178
30. C.N. Abou Chakra, J. Pepin, and L. Valiquette Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review PLoS One 7 2012 e30258 e30265
31. P.R. Gibson, and J.G. Muir Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut 54 2005 900 903
32. C. Perrier, N. Sprenger, and B. Corthésy Glycans on secretory component participate in innate protection against mucosal pathogens J Biol Chem 281 2006 14280 14287
33. A. Phalipon, A. Cardona, and J.P. Kraehenbuhl et al. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo Immunity 17 2002 107 115
34. S. Johnson, D.N. Gerding, and E.N. Janoff Systemic and mucosal antibody responses to toxin A in patients with Clostridium difficile J Infect Dis 166 1992 1287 1294
35. J. O'Horo, and N. Safdar The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review Int J Infect Dis 13 2009 663 667
36. J. Steele, K. Chen, and X. Sun et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models J Infect Dis 205 2012 384 391
37. H. Stubbe, J. Berdoz, J.P. Kraehenbuhl, and B. Corthésy Polymergic IgA is superior monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers J Immunol 164 2000 1952 1960
38. C.P. Kelly, C. Pothoulakis, J. Orellana, and J.T. LaMont Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding Gastronterology 102 1992 35 40
39. C.P. Quan, A. Berneman, and R. Pires et al. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans Infect Immun 65 1997 3997 4004
40. C.P. Kelly, S. Chetham, and S. Keates et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract Antimicrob Agents Chemother 41 1997 236 241
41. J. Steele, J. Sponseller, and D. Schmidt et al. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile Hum Vaccin Immunother 9 2013 1565 1568